Topics:

FDA removes partial hold on Telcyta clinical development

FDA removes partial hold on Telcyta clinical development

PALO ALTO, California—Telik, Inc. has announced that the FDA has removed the partial hold on Telcyta (canfosfamide HCl) clinical trials. This action follows a complete review of Telcyta data by the agency and permits the resumption of Telcyta clinical development. Telcyta is a tumor-activated small-molecule product candidate in clinical development for the treatment of advanced ovarian cancer and non-small-cell lung cancer. FDA placed the hold on development after phase III data showed lower median survival for women with advanced ovarian cancer receiving Telcyta vs standard chemotherapy.

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.